ClinicalTrials.gg
TerminatedNCT04893018Updated Jun 27, 2024Results posted

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

A Phase 1 interventional study of Efineptakin alfa in AIDS-Related Kaposi Sarcoma, HIV Infection and Kaposi Sarcoma, sponsored by Fred Hutchinson Cancer Center. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Fred Hutchinson Cancer Center · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Terminated due to end of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in AIDS-related Kaposi sarcoma with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. AIDS-related Kaposi sarcoma · United States.

Enrollment
20th of 22
8 · median 29
Started
2022
the only one that year
Phase 1
12 of 33
none open now
Registered
31st of 33
by date
Lead sponsor
1 of 33
Fred Hutchinson Cancer Center

Among the 33 studies in AIDS-related Kaposi sarcoma with a site in United States, this one is the 20th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2022, is one of 12 in phase 1, and was the 31st registered.

AIDS-related Kaposi sarcoma

43 studies on the registry are indexed under AIDS-related Kaposi sarcoma; 2 are open to participants now.

Browse AIDS-related Kaposi sarcoma studies →

Open to participants now

1 of the 33 studies in AIDS-related Kaposi sarcoma with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 AIDS-related Kaposi sarcoma study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in AIDS-related Kaposi sarcoma with a site in United States, or all of them as a file.
02

Study summary

This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT-I7 may work better in treating Kaposi sarcoma.

Read the detailed description

OUTLINE: This is a dose-escalation study.

Patients receive efineptakin alfa intramuscularly (IM) on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up on day 30 (+/- 7 days) and then every 12 weeks for 12 months.

03

Conditions studied

  • AIDS-Related Kaposi Sarcoma
  • HIV Infection
  • Kaposi Sarcoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed Kaposi sarcoma
  • Patients must have evaluable disease. Note: Kaposi sarcoma will be evaluated using a modified version (consistent with National Cancer Institute [NCI] studies) of the Acquired Immunodeficiency Syndrome (AIDS) Clinical Trial Group (ACTG) Oncology Committee staging and response definitions for KS
  • No upper or lower limit on the number of prior therapies or stage of disease
  • -positive patients must have been on effective anti-retroviral (ART) therapy for at least 3 months prior to enrollment, with persistent KS affecting quality of life due to either T1 disease or T0 disease with inadequate disease regression on ART alone
  • HIV-positive patients must have undetectable HIV viral loads =\< 40 copies/mL measured using a Food and Drug Administration (FDA)-approved commercial assay with lower limit of detection between =\< 20 copies/mL and =\< 40 copies/mL
  • Patients with visceral involvement must:

    • Meet other eligibility criteria
    • Have any/all associated tumor associated symptoms =\< grade 2 by (CTCAE) criteria; and/or
    • Require no immediate intervention (e.g. mild oozing of oral KS not an exclusion criteria)
  • Patients must provide newly obtained core, punch, or excisional of a tumor lesion obtained up to 28 days prior to treatment initiation. An archival tumor sample obtained within 1 year of screening is allowed if pre treatment biopsy is deemed unsafe or technically not feasible
  • Patients must be >= 18 years of age on day of signing document. Because no dosing or adverse event data are currently available on the use of NT-I7 in patients \< 18 years of age, children are excluded from this study but will be eligible for future pediatric trials
  • (ECOG) performance status =\< 2 ( >= 60%)
  • Leukocytes >= 2,500/mcL
  • >= 1,000/mcL
  • >= 100,000/mcL
  • >= 9/dL
  • Total =\< 1.5 institutional (ULN) OR \< 3 x institutional ULN for Gilbert's syndrome or HIV protease inhibitors
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =\< 2.5 x institutional ULN
  • Creatinine =\< 2 x institutional ULN OR >= 60 mL/min/1.73 m\^2 by Cockcroft-Gault. At the discretion of the treating physician, a 24-hour urine creatinine clearance could be obtained and utilized as the gold standard if creatinine clearance by Cockcroft-Gault is \< 30 and prevents patient enrollment on the trial
  • Patients with chronic virus (HBV) infection must be on suppressive antiviral therapy
  • Patients with a history of virus (HCV) infection must have an undetectable HCV viral load due to prior treatment or natural resolution
  • Female patients of must have a negative urine or serum pregnancy test within 72 hours before receiving the first dose of the study agent. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • The effects of NT-I7 on the developing human fetus are unknown. For this reason and because NT-I7 may have an adverse effect on pregnancy and poses risk to the human fetus, women of child-bearing potential and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 90 days after completion of NT-I7 administration
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

Exclusion Criteria:

  • Patients who have had chemotherapy, radiotherapy or other KS directed therapy other than ART for within 2 weeks before the initiation of study treatment
  • Patients who have not recovered from immune related adverse events due to prior therapy (i.e., have residual toxicities > grade 1) with the exception of hypothyroidism managed by supplemental levothyroxine
  • Patients who have received treatment with any other agent within 4 weeks before initiation of study treatment
  • Patients with known to Chinese hamster ovary cell products or other recombinant human antibodies
  • Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2, pomalidomide, or ) within 6 weeks before initiation of study treatment
  • Patients who have received treatment with systemic medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor [anti-TNF] agents) within 2 weeks before initiation of study treatment

    • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled;
    • The use of inhaled , and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • Patients who have a history or risk of disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Note: the following will NOT be exclusionary:

    • The presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody (ANA) titer or lupus anticoagulant) without associated symptoms
    • Clinical evidence of vitiligo or other forms of depigmenting illness
    • Mild autoimmunity not impacting the function of major organs (e.g., limited psoriasis)
  • Patients with uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure ( Class III or IV), unstable angina pectoris, cardiac arrhythmia, recent myocardial infarction (within the last 6 months). Patients with known history of treatment with cardiotoxic agents, including anthracyclines, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because the effects of NT-I7 on the developing human fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with NT-I7, breastfeeding should be discontinued if the mother is treated with NT-I7
  • Patients with a history of solid organ or stem cell transplant
  • Patients with continuing KS regression on ART alone. Stable disease allowed
  • Patients with a prior or concurrent requiring active therapy
  • Patients with active tuberculosis
  • Patients who have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening X-Ray. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treatment (efineptakin alfa)

    Patients receive efineptakin alfa IM on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

    Biological: Efineptakin alfa

Interventions

  • Given IM

    Also known as: 2026634-47-7, GX-I7, Hyleukin-7 (TM), Il-7 Hybrid Fc, IL-7-hyFc, NT-I7, rhIL-7-hyFc

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    Measured by Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 30 days after last dose of NT-I7, approximately 31 weeks total

Secondary outcomes

  1. Objective Response Rate (ORR).

    Defined as the proportion of participants who achieved Complete Response (CR) or Partial Response (PR) according to modified Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group Criteria (ACTG) criteria.

    Time frame: 12 months

  2. Duration of Response (DOR)

    Measured in participants who obtain a partial response or better and defined as time from the best response within the first 36 weeks of therapy until disease progression or censoring. Kaplan Meier survival estimates constructed for each of these survival endpoints with 95% confidence intervals (CIs), for up to 1 year following initiation of treatment in all participants.

    Time frame: Up to 1 year

  3. Progression-free Survival (PFS)

    Defined as the time from administration of the first dose of NT-I7 until disease progression or death or censoring. Kaplan Meier survival estimates will be constructed for each of these survival endpoints with 95% CIs, for up to 1 year following initiation of treatment in all participants.

    Time frame: Assessed up to 1 year

  4. Overall Survival (OS)

    From administration of the first dose of NT-I7 until death or censoring. Kaplan Meier survival estimates will be constructed for each of these survival endpoints with 95% CIs.

    Time frame: Assessed up to 1 year following initiation of treatment

  5. Effect of NT-I7 on Kinetics of Absolute Lymphocyte Counts (ALC) in Blood

    For analysis of circulating lymphocytes, we will describe fold-change (median and range) in blood ALC. Fold change from baseline is defined as the ratio of the value at the visit to that at baseline.

    Time frame: From pre-administration to each time point following first administration (1, 4, and 9 weeks)

  6. Effect of NT-I7 on Kinetics of CD4+ T Cells in Blood.

    Described by fold-change (median and range) in blood CD4+ T cells. Fold change from baseline is defined as the ratio of the value at the visit to that at baseline.

    Time frame: From pre-administration to each time point following first administration (1, 4, and 9 weeks)

  7. Effect of NT-I7 on Kinetics of CD8+ T Cells in Blood.

    Described by fold-change (median and range) in blood CD8+ T cells. Fold change from baseline is defined as the ratio of the value at the visit to that at baseline.

    Time frame: From pre-administration to each time point following first administration (1, 4, and 9 weeks)

Other outcomes

  1. Immunogenicity of NT-I7

    The proportion of participants developing neutralizing antibodies will be summarized.

    Time frame: Up to 12 months after last dose of NT-I7

07

Results

Posted Jun 27, 2024
Limitations and caveats
Enrollment for this study was terminated early due end of funding. Some of the planned statistical analyses were not performed.

Participant flow

Participant flow — Overall Study
MilestoneNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Started62
Completed20
Not completed42
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject20
Withdrew: Study terminated12

Outcome measures

PrimaryPercentage of Participants With Adverse Events

Measured by Common Terminology Criteria for Adverse Events version 5.0.

Time frame:
Up to 30 days after last dose of NT-I7, approximately 31 weeks total
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Percentage of Participants With Adverse Events100100
SecondaryObjective Response Rate (ORR).

Defined as the proportion of participants who achieved Complete Response (CR) or Partial Response (PR) according to modified Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group Criteria (ACTG) criteria.

Time frame:
12 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR).
ParticipantsNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Complete Response (CR)00
Partial Response (PR)12
Objective Response Rate (CR+PR)12
SecondaryDuration of Response (DOR)

Measured in participants who obtain a partial response or better and defined as time from the best response within the first 36 weeks of therapy until disease progression or censoring. Kaplan Meier survival estimates constructed for each of these survival endpoints with 95% confidence intervals (CIs), for up to 1 year following initiation of treatment in all participants.

Time frame:
Up to 1 year
Reported as:
Median · months
Duration of Response (DOR)
monthsNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Duration of Response (DOR)NA (NA to NA)NA (NA to NA)
SecondaryProgression-free Survival (PFS)

Defined as the time from administration of the first dose of NT-I7 until disease progression or death or censoring. Kaplan Meier survival estimates will be constructed for each of these survival endpoints with 95% CIs, for up to 1 year following initiation of treatment in all participants.

Time frame:
Assessed up to 1 year
Reported as:
Median · months
Progression-free Survival (PFS)
monthsNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Progression-free Survival (PFS)NA (2.1 to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

From administration of the first dose of NT-I7 until death or censoring. Kaplan Meier survival estimates will be constructed for each of these survival endpoints with 95% CIs.

Time frame:
Assessed up to 1 year following initiation of treatment
Reported as:
Median · months
Overall Survival (OS)
monthsNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryEffect of NT-I7 on Kinetics of Absolute Lymphocyte Counts (ALC) in Blood

For analysis of circulating lymphocytes, we will describe fold-change (median and range) in blood ALC. Fold change from baseline is defined as the ratio of the value at the visit to that at baseline.

Time frame:
From pre-administration to each time point following first administration (1, 4, and 9 weeks)
Reported as:
Median · No units, median and IQR of ratios
Effect of NT-I7 on Kinetics of Absolute Lymphocyte Counts (ALC) in Blood
No units, median and IQR of ratiosNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Week 11.06 (0.62 to 1.10)1.15 (1.06 to 1.24)
Week 43.20 (3.20 to 3.47)3.93 (3.29 to 4.58)
Week 93.01 (2.65 to 3.12)3.24 (2.96 to 3.52)
SecondaryEffect of NT-I7 on Kinetics of CD4+ T Cells in Blood.

Described by fold-change (median and range) in blood CD4+ T cells. Fold change from baseline is defined as the ratio of the value at the visit to that at baseline.

Time frame:
From pre-administration to each time point following first administration (1, 4, and 9 weeks)
Reported as:
Median · No units, median and IQR of ratios
Effect of NT-I7 on Kinetics of CD4+ T Cells in Blood.
No units, median and IQR of ratiosNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Week 11.26 (0.76 to 1.71)1.19 (0.84 to 1.54)
Week 44.46 (3.07 to 5.92)6.30 (4.95 to 7.66)
Week 93.26 (2.18 to 4.19)4.45 (3.42 to 5.47)
SecondaryEffect of NT-I7 on Kinetics of CD8+ T Cells in Blood.

Described by fold-change (median and range) in blood CD8+ T cells. Fold change from baseline is defined as the ratio of the value at the visit to that at baseline.

Time frame:
From pre-administration to each time point following first administration (1, 4, and 9 weeks)
Reported as:
Median · No units, median and IQR of ratios
Effect of NT-I7 on Kinetics of CD8+ T Cells in Blood.
No units, median and IQR of ratiosNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Week 10.89 (0.78 to 1.14)1.29 (1.27 to 1.32)
Week 43.25 (2.43 to 4.48)4.12 (3.45 to 4.79)
Week 92.53 (1.84 to 3.42)3.28 (2.93 to 3.64)
Other pre-specifiedImmunogenicity of NT-I7

The proportion of participants developing neutralizing antibodies will be summarized.

Time frame:
Up to 12 months after last dose of NT-I7

Results for this outcome have not been posted.

Adverse events

Collected over All-Cause Mortality was assessed through study completion, up to 12 months; serious adverse events and other (not including serious) adverse events were assessed from the time of the first dose until 30 days after the last dose of NT-I7, approximately 31 weeks total.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NT-I7 (Efineptakin Alfa) Dose Level 10/6 (0%)1/6 (16.7%)6/6 (100%)
NT-I7 (Efineptakin Alfa) Dose Level 20/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
BacteremiaInfections and infestations0/61/2
ChylothoraxRespiratory, thoracic and mediastinal disorders0/61/2
Pleural effusionRespiratory, thoracic and mediastinal disorders0/61/2
Injection site reactionGeneral disorders1/60/2
Most frequent other events
Showing 10 of 46
Most frequent other events
EventNT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2
Alanine aminotransferase increasedInvestigations6/60/2
Creatinine increasedInvestigations0/62/2
Neutrophil count decreasedInvestigations0/62/2
HyponatremiaMetabolism and nutrition disorders0/62/2
Injection site reactionGeneral disorders4/61/2
Aspartate aminotransferase increasedInvestigations4/61/2
AnemiaBlood and lymphatic system disorders2/61/2
Axillary lymphadenopathyBlood and lymphatic system disorders0/61/2
Anal painGastrointestinal disorders0/61/2
NauseaGastrointestinal disorders1/61/2

Baseline characteristics

Population included all enrolled participants.

Age, Categorical
Age, Categorical(Participants)NT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2Total
<=18 years000
Between 18 and 65 years527
>=65 years101
Age, Continuous
Age, Continuous(years)NT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2Total
Mean57.2 ± 7.237.0 ± 5.752.1 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)NT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2Total
Female000
Male628
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2Total
Hispanic or Latino101
Not Hispanic or Latino527
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White516
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)NT-I7 (Efineptakin Alfa) Dose Level 1NT-I7 (Efineptakin Alfa) Dose Level 2Total
United States628
08

Study locations

3 sites
  • Zuckerberg San Francisco General Hospital
    San Francisco, California 94110, United States
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
  • Harborview Medical Center
    Seattle, Washington 98104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2023, 18 months.

Results were first posted in Jun 2024, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2021
First posted
May 19, 2021
StartActual
May 23, 2022
Primary completionActual
Dec 15, 2023
CompletionActual
Dec 15, 2023
Results first posted
Jun 27, 2024
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04893018
Collaborators
Cancer Immunotherapy Trials Network (CITN), National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
May 19, 2021
Start date
May 23, 2022
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023
Results posted
Jun 27, 2024
Last update
Jun 27, 2024

Study contacts

Chia-Ching (Jackie) Wang
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efineptakin alfa

Start the discussion